Zydus Looks To Revlimid Opportunity, Pivots To Multivariant COVID-19 Vaccine
Board Approves Share Buyback
Executive Summary
Zydus is looking to launch a Revlimid generic in the second wave while an opportunity might soon emerge from Takeda’s Pentasa. It is also pivoting to a multivariant version of its plasmid DNA vaccine against COVID-19, ZyCoV-D, after the original didn’t receive an encouraging response.